申请人:Kissei Pharmaceutical Co., Ltd.
公开号:US06376707B1
公开(公告)日:2002-04-23
The present invention relates to a crystalline polymorph of 2-[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxy-phenyl)-1-methylethyl]amino]ethyl]phenoxy]acetic acid having strong diffraction peaks (diffraction angle: 2&thgr;±0.1°) at 10.8, 19.1, 19.3, 19.8, 20.6 and 27.0° in powder X-ray diffraction pattern, which has potent &bgr;2- and &bgr;3-adrenoceptor stimulating effects and is useful as an agent for relieving pain and promoting the removal of calculi in urolithiasis, and the like. For example, the crystalline polymorph can be prepared by hydrolyzing ethyl 2-[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-amino]ethyl]phenoxy]acetate phosphate by sodium hydroxide, adding an aqueous phosphoric acid solution at 40° C. and over, adding a mixed solvent of water and methanol or methanol to the resulting compound, and stirring the suspension at 40° C. to reflux temperature for 30 minutes to several hours.
本发明涉及一种结晶多型体,其在粉末X射线衍射图谱中具有强烈的衍射峰(衍射角:2θ±0.1°),在10.8、19.1、19.3、19.8、20.6和27.0°处,该结晶多型体具有强效的β2-和β3-肾上腺素受体刺激作用,并可用作缓解疼痛和促进泌尿结石中结石的排出等药物。例如,该结晶多型体可通过水解乙酰2-[4-[2-[(1S,2R)-2-羟基-2-(4-羟基苯基)-1-甲基乙基]氨基]乙基]苯氧乙酸酯磷酸酯,加入40°C以上的水磷酸溶液,加入水和甲醇或甲醇的混合溶剂到所得化合物中,将悬浮液在40°C至沸腾温度搅拌30分钟至几小时来制备。